Thalidomide pharmacokinetics in sheep

References

• Aho AD, McNulty AM, Coussens PM. Enhanced expression of interleukin 1 alpha and tumour necrosis factor alpha receptor associated protein 1 in ileal tissues of cattle infected with Mycobacterium avium subsp paratuberculosis. Infection and Immunity 71, 6479–86, 2003 doi: 10.1128/IAI.71.11.6479-6486.2003
   PubMed Web of Science ®Google Scholar
• Alzuherri HM, Woodall CJ, Clarke CJ. Increased intestinal TNFα, IL-1β, and IL-6 expression in ovine paratuberculosis. Veterinary Immunology and Immunopathology 49, 331–45, 1996 doi: 10.1016/0165-2427(95)05477-4
   PubMed Web of Science ®Google Scholar
• Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumour necrosis factor production in patients with leprosy. Infection and Immunity 60, 1441–6, 1992
   PubMed Web of Science ®Google Scholar
• Boughton BJ, Sheehan TMT, Wood J, O'Brian D, Butler M, Simpson A, Hale KA. High performance liquid chromatography assay of plasma thalidomide: Stabilisation of specimens and determination of tentative therapeutic range for chronic graft versus host disease. Annals of Clinical Biochemistry: An International Journal of Biochemistry and Laboratory Medicine 32, 79–83, 1995 doi: 10.1177/000456329503200108
   Google Scholar
• Clancy R, Ren Z, Turton J, Pang G, Wettstein A. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion. Digestive and Liver Disease 39, 445–51, 2007 doi: 10.1016/j.dld.2006.12.006
   Web of Science ®Google Scholar
• Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary clinical experience. The American Journal of Gastroenterology 95, 3469–77, 2000 doi: 10.1111/j.1572-0241.2000.03363.x
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 91, 4082–5, 1994 doi: 10.1073/pnas.91.9.4082
   PubMed Web of Science ®Google Scholar
• Erickson T, Bjorkman S, Fyge A, Ekberg H. Determination of thalidomide in plasma and blood by high performance liquid chromatography: avoiding hydrolytic degradation. Journal of Chromatography B: Biomedical Sciences and Applications 582, 211–6, 1992 doi: 10.1016/0378-4347(92)80321-G
   Web of Science ®Google Scholar
• *Gabrielsson J, Weiner D. Non-compartmental analysis. In: Reisfeld B, Mayeno AN (eds). Computational Toxicology. Vol. I. Pp. 377–89. Humana Press, Stockholm, Sweden, 2012
   Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 130, 323–33, 2006 doi: 10.1053/j.gastro.2005.11.030
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukaemia 18, 624–7, 2004 doi: 10.1038/sj.leu.2403285
   PubMed Web of Science ®Google Scholar
• Lazzerini M, Martelossi S, Magazzu G, Pelligrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Lorusso M et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn's disease. A randomised clinical trial. Journal of the American Medical Association 310, 2164–73, 2013 doi: 10.1001/jama.2013.280777
   PubMed Web of Science ®Google Scholar
• Lyon AW, Duran G, Raisys VA. Determination of thalidomide by high performance liquid chromatography; methodological strategy for clinical trials. Clinical Biochemistry 28, 467–70, 1995 doi: 10.1016/0009-9120(95)00019-6
   PubMed Web of Science ®Google Scholar
• Masson P. Quality control techniques for routine analysis with liquid chromatography in laboratories. Journal of Chromatography A 1158, 168–73, 2007. doi: 10.1016/j.chroma.2007.03.003
   PubMed Web of Science ®Google Scholar
• Matthews SJ, McCoy C. Thalidomide: A review of approved and investigational uses. Clinical Therapeutics 25, 342–95, 2003 doi: 10.1016/S0149-2918(03)80085-1
   PubMed Web of Science ®Google Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation. Journal of Experimental Medicine 177, 1675–80, 1993 doi: 10.1084/jem.177.6.1675
   PubMed Web of Science ®Google Scholar
• Muller GW, Konnecke WE, Smith AM, Khetani VD. A concise two step synthesis of thalidomide. Organic Process Research and Development 3, 139–40, 1999 doi: 10.1021/op980201b
   Web of Science ®Google Scholar
• Nakase H, Tamaki H, Matsuura M, Chiba T, Okazaki K. Involvement of Mycobacterium avium subspecies paratuberculosis in TNF-α production from macrophage: Possible link between MAP and immune response in Crohn's disease. Inflammatory Bowel Diseases 17, 140–2, 2011 doi: 10.1002/ibd.21750
   Web of Science ®Google Scholar
• Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111, 3968–77, 2008 doi: 10.1182/blood-2007-10-117457
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Review 26, 351–62, 2000 doi: 10.1053/ctrv.2000.0188
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumour necrosis factor alpha production by stimulated human monocytes. Journal of Exploratory Medicine 173, 699–703, 1991 doi: 10.1084/jem.173.3.699
   PubMed Web of Science ®Google Scholar
• Scribano ML, Cantoro L, Marrollo M, Cosintino R, Kohn A. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant to anti-TNFa drugs. Clinical Gastroenterology 3, 48–54, 2014
   Google Scholar
• Shannon EJ, Morales MJ, Sandoval F. Immunomodulatory assays to study the structure – Activity relationship of Thalidomide. Immunopharmacology 35, 203–12, 1997 doi: 10.1016/S0162-3109(96)00149-X
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M et al. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine 341, 1565–71, 1999 doi: 10.1056/NEJM199911183412102
   PubMed Web of Science ®Google Scholar
• Teo SK, Colburn WA, Thomas SD. Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. Journal of Clinical Pharmacology 39, 1162–68, 1999
   PubMed Web of Science ®Google Scholar
• Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Thalidomide in the treatment of leprosy. Microbes and Infection 4, 1193–202, 2002 doi: 10.1016/S1286-4579(02)01645-3
   PubMed Web of Science ®Google Scholar
• Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Journal of the American Academy of Dermatology 35, 969–79, 1996 doi: 10.1016/S0190-9622(96)90122-X
   PubMed Web of Science ®Google Scholar
• Walker SL, Waters MF, Lockwood DN. The role of thalidomide in the management of erythema nodosum leprosum. Leprosy Review 78, 197–215, 2007
   PubMed Web of Science ®Google Scholar
• Zheng CF, Xu JH, Leung YK. Treatment of pediatric refractory Crohn's disease with thalidomide. World Journal of Gastroenterology 17, 1286–91, 2011 doi: 10.3748/wjg.v17.i10.1286
   PubMed Web of Science ®Google Scholar
• Zhou S, Li Y, Kestell P, Paxton JW. Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B 785, 165–73, 2003 doi: 10.1016/S1570-0232(02)00911-X
   PubMed Web of Science ®Google Scholar